Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 5, 2024
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Alignment with FDA on Development Pathway for Lomecel-B(TM) in HLHS
September 3, 2024
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). The meeting supported the advancement of Lomecel-B(TM), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, will be spotlighted at next month’s H.C. Wainwright 26th Annual Global Investment Conference; the event is scheduled for Sept. 9–11, 2024. According to the announcement, company officials are slated to present on Sept. 10 at 5 p.m. […]
InvestorNewsBreaks — MetAlert Inc. (MLRT) Receives GPS SmartSoles PO from Mexico-Based Security Solutions Provider
August 15, 2024
MetAlert (OTC: MLRT), a pioneer in GPS wearable technology and global provider in the field of human and asset-tracking and recovery systems, has received an initial order for GPS SmartSoles(R) from Skyangel Security headquartered in Mexico City, Mexico. According to the announcement, the partnership with Skyangle, a company committed to providing top-tier security solutions across […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights
August 15, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is reporting on its second-quarter 2024 financial results, as well as key business milestones. Highlights of the report include positive data from LGNV’s phase 2a clinical trial designed to evaluate Lomecel-B(TM) in Alzheimer’s disease being presented at the […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference Call
August 6, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is planning to release its second-quarter 2024 financial report after markets close on Aug. 14, 2024. The company also announced that it has scheduled a conference call and webcast on the same day to discuss the report […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Lomecel-B(TM) Study Results Presented at the Alzheimer’s Association International Conference
July 29, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is presenting results from its Clear Mind phase 2a clinical trial at the Alzheimer’s Association International Conference(R) (“AAIC”). The conference began on July 28, 2024, and runs through Aug. 1, 2024; the event is being held in person […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on $9M Registered Direct Offering
July 22, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market following NASDAQ rules, included the issue and sale of 2,236,026 shares of LGVN Class A common stock (or common stock equivalents in […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Enters into $9M Registered Direct Offering
July 18, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has entered into definitive agreements for the issue and sale of shares of Class A common stock. According to the announcement, the registered direct offering is comprised of up to 2,236,026 shares of LGVN Class A common […]
InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Lomecel-B(TM) Granted Fast Track Designation for Treatment of Mild Alzheimer’s Disease
July 17, 2024
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease. Lomecel-B(TM) is a proprietary, scalable, allogeneic, investigational cellular therapy being evaluated […]
InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Lomecel-B(TM) Granted RMAT Designation for the Treatment of Mild Alzheimer’s Disease
July 10, 2024
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (“FDA”) granted Regenerative Medicine Advanced Therapy (“RMAT”) designation to Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. To the company’s knowledge based on publicly available information, […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Elected New Board Member at Annual Stockholder Meeting
July 9, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (“HLHS”) and Alzheimer’s disease, is announcing an addition to its board of directors. According to the announcement, senior healthcare investment banker Neha Motwani was elected to the board during the company’s recent Annual Meeting of […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Strategic Board Appointment of Gene Therapy Pioneer Roger Hajjar, MD
July 8, 2024
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has appointed Roger Hajjar, MD, director of the Gene and Cell Therapy Institute at Mass General Brigham, to its board of directors. An internationally recognized scientist, Dr. Hajjar’s cardiac gene therapy discoveries have spurred clinical trials […]
InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Presentation at Virtual Life Sciences Investor Forum Made Available for Online Viewing
June 21, 2024
Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions. Longeveron presented at the Virtual Life Sciences Investor Forum on June 20. The company’s presentation is now available for online viewing 24/7 for 90 days. To view the presentation, visit https://ibn.fm/RYzP8 To view the […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for $4.4M, Present at Virtual Life Sciences Investor Forum
June 17, 2024
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced its entry into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces CEO Participation in Emerging Growth Conference, Completion of Investigator Meeting for Phase 2b Clinical Trial
June 11, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is participating in this week’s Emerging Growth Virtual Conference. The agenda for the event indicates Longeveron CEO and director Mohamed Wa’el Hashad will be speaking tomorrow at 1:45 p.m. ET; the two-day conference is slated for June […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Participate in Upcoming Emerging Growth Virtual Conference
June 10, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines, will be presenting at the Emerging Growth Virtual Conference this week. The two-day event is scheduled for June 12–13, 2024. Longeveron’s presentation is slated to begin at 1:45 p.m. ET on Wednesday, June 12. According to the announcement, anyone interested can view the presentation on […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Launches New Business, Eyes Opportunity in Contract Manufacturing
June 3, 2024
Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. The company today announced the launch of its contract development and manufacturing business at its 15,000-square-foot, state-of-the-art Good Manufacturing Practice (“GMP”) facility. In addition, the company announced the initiation of work under its first manufacturing […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Set to Participate in Upcoming BIO International Convention 2024
May 28, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at next month’s 2024 BIO International Convention; the convention is scheduled to take place June 3–6, 2024, in San Diego, California. According to the announcement, Longeveron officials will meet with executives from global pharmaceutical companies […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Financial Report, Business Update for Q1 2024
May 15, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting financial results and a business update for the first quarter of 2024, the period ended March 31, 2024. Highlights of the report include that the company’s phase 2b clinical trial evaluating Lomecel-B(TM) in rare pediatric disease […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Planned Transitions for Board of Directors
May 13, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of business development and corporate licensing for Merck & Co. Inc., has been appointed to the board; Dr. […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call/Webcast
May 2, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be releasing its first-quarter 2024 financial results this month. The company announced that it will release the report, along with a business update, on May 14, […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Presenting at This Week’s Planet MicroCap Showcase
April 29, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, is one of 96 companies slated to participate at the Planet MicroCap Showcase: VEGAS. The three-day event begins in Las Vegas tomorrow and runs through May 2, 2024. The event kicks off with “MicroCap Investing Workshop,” which features widely recognized financial influencers, investors, fund managers […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate in Upcoming Planet MicroCap Showcase
April 26, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month’s Planet MicroCap Showcase. The conference is slated for May 1–2, 2024, in Las Vegas. According to the announcement, Longeveron’s presentation is scheduled to begin at 4:30 p.m. PT. An archived copy of the webcast will be available on the […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Multimillion-Dollar Warrant Exercise Offering, Public Offering
April 19, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its warrant exercise offering. According to the announcement, the exercise comprised certain existing warrants to purchase 2,399,744 shares of LGVN Class A common stock; […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M
April 17, 2024
Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. The company today announced its entry into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its […]
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Share CLEAR MIND Study Results in Featured Research Oral Presentation at 2024 AAIC
April 15, 2024
Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the company’s CLEAR MIND Phase 2a study results. A Phase 2a randomized clinical trial, CLEAR-MIND is evaluating Lomecel-B(TM) in mild Alzheimer’s disease. In addition to the study results, Longeveron […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M
April 12, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its previously announced public offering. The offering was comprised of up to 2,234,043 shares of Class A LGVN common stock (or prefunded warrants in […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering
April 9, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has announced the pricing of its public offering. The offering is comprised of 2,234,043 shares of the company’s Class A common stock (or prefunded warrants) and warrants […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Shareholder Letter, Discussing Strategy, Pipeline and Priorities
April 8, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a letter to shareholders outlining its strategy and noting its clinical pipeline and this year’s priorities and goals. According to the letter from Longeveron CEO Wa’el Hashad, the last year has been focused on develop a strategic roadmap built […]
Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update
March 28, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split
March 20, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock. The move was approved by the company’s board of directors during a special stockholder meeting. According to the announcement, the reverse split will become effective at 11:59 p.m. […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports on Year-End 2023 Financial Results, Corporate Update
February 28, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report also included a corporate update. The report noted that revenues for 2023 totaled $0.7 million with grant revenue for 2023 being less than $0.1 million; related cost […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results, Corporate Update
February 22, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The company announced that it will release its 2023 financial results after market close on Feb. 27, 2024, and will host a conference call at 5 p.m. ET that […]
InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) ELPIS Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS Patients
February 21, 2024
Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with hypoplastic left heart syndrome (‘HLHS’) during […]
Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association
February 7, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions including hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty has evaluated – and still is evaluating – its lead investigational therapeutic candidate Lomecel-B(TM), an allogeneic, bone marrow-derived medicinal signaling cell (“MSC”) therapy product, in multiple clinical trials. One […]
InvestorNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)
February 6, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was spotlighted in a recent H.C. Wainwright & Co. research report after the Company’s announcement about receiving a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for a patent application related to the use of Lomecel-B(TM) […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Granted US Patent Allowance for Key Technology Behind Lead Investigation Product
January 29, 2024
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has received notice from the United States Patent and Trademark Office (“USPTO”) of patent allowance for Medicinal Signaling Cells (“MSCs”). The patent covers the technology behind LGVN’s lead investigational product Lomecel-B(TM) and will impact patients with Aging-related Frailty receiving […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Enters Definitive Agreement for $2.36M Registered Direct Offering
December 21, 2023
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has announced a $2.36 million registered direct offering. The company entered into a definitive agreement for the issue and sale of 1,355,301 shares of common stock, priced […]
InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports Additional Positive Clinical Data, Imaging Biomarker Results in Phase 2a Lomecel-B(TM) Trial
December 20, 2023
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is releasing new clinical and biomarker results from the CLEAR MIND trial of its investigational product Lomecel-B(TM). The phase 2a trial evaluates Lomecel-B for the treatment of […]